Cardiff Oncology, Inc.(CRDF)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRDF Cardiff Oncology, Inc.

休市中 05-22 16:00:00 EDT

1.78

-0.01

-0.56%

盘后1.80

+0.02+1.12%

19:59 EDT

最高1.82	最低1.68	成交量126.27万
今开1.81	昨收1.79	日振幅7.82%
总市值1.22亿	流通市值1.17亿	总股本6,836万
成交额218.89万	换手率1.92%	流通股本6,573万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRDF","market":"US","secType":"STK","nameCN":"Cardiff Oncology, Inc.","latestPrice":1.78,"timestamp":1779480000000,"preClose":1.79,"halted":0,"volume":1262718,"hourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.78,"latestTime":"19:59 EDT","volume":18759,"amount":33436.1049,"timestamp":1779494347827,"change":0.02,"changeRate":0.011236,"amplitude":0.016854},"delay":0,"changeRate":-0.005586592178770954,"floatShares":65730400,"shares":68364979,"eps":-0.665507,"marketStatus":"休市中","change":-0.01,"latestTime":"05-22 16:00:00 EDT","open":1.81,"high":1.82,"low":1.68,"amount":2188930.9971132,"amplitude":0.078212,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.665507,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":1.79,"preHourTrading":{"tag":"盘前","latestPrice":1.8067,"preClose":1.79,"latestTime":"09:22 EDT","volume":8912,"amount":15974.5915632,"timestamp":1779456161704,"change":0.0167,"changeRate":0.00933,"amplitude":0.039106},"postHourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.78,"latestTime":"19:59 EDT","volume":18759,"amount":33436.1049,"timestamp":1779494347827,"change":0.02,"changeRate":0.011236,"amplitude":0.016854},"volumeRatio":0.7472438121671533,"impliedVol":1.1935,"impliedVolPercentile":0.5219},"requestUrl":"/m/hq/s/CRDF","defaultTab":"news","newsList":[{"id":"1151982459","title":"Cardiff Oncology, Inc. 寻求针对 Nms 的禁令救济与确认判决 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1151982459","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151982459?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:03","pubTimestamp":1779224612,"startTime":"0","endTime":"0","summary":"Cardiff Oncology, Inc. 已通过提交给美国证券交易委员会的文件披露，该公司正针对Nms提起诉讼，寻求法院的禁令救济以及一项确认判决。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182918615","title":"Cardiff Oncology, Inc. 就Onvansertib许可协议违约对Nerviano Medical Sciences提起诉讼 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1182918615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182918615?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:03","pubTimestamp":1779224604,"startTime":"0","endTime":"0","summary":"Cardiff Oncology, Inc.  已向美国证券交易委员会提交文件，披露其已对Nerviano Medical Sciences提起诉讼，指控后者违反了关于在研药物Onvansertib的许可协议。根据提交的SEC文件，Cardiff Oncology指控Nerviano Medical Sciences未能履行其在许可协议项下的义务，构成了违约行为。此次诉讼的核心争议点围绕Onvansertib的相关权利与责任展开。该法律行动标志着双方在Onvansertib开发合作上出现了重大分歧。Cardiff Oncology通过此举旨在寻求法律救济，以维护其基于该许可协议所享有的权益。事件的发展可能对Onvansertib未来的研发与商业化进程产生影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127493618","title":"Cardiff Oncology任命Josh Muntner为首席财务官、Ajay Aggarwal为首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=1127493618","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127493618?lang=zh_cn&edition=full","pubTime":"2026-04-10 04:02","pubTimestamp":1775764943,"startTime":"0","endTime":"0","summary":"Cardiff Oncology, Inc.宣布两项重要人事任命：Josh Muntner将于4月6日起担任公司首席财务官，而Ajay Aggarwal则自4月27日起出任首席运营官。\n此次高层人事变动将进一步加强公司管理团队实力，为后续战略发展提供重要支撑。两位高管在生物制药领域均拥有丰富的财务管理及运营经验，他们的加入有望推动公司在肿瘤治疗领域的研发与商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614011420","title":"Cardiff Oncology, Inc.盘中异动 股价大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614011420","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614011420?lang=zh_cn&edition=full","pubTime":"2026-02-27 00:16","pubTimestamp":1772122584,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日00时16分，Cardiff Oncology, Inc.股票出现异动，股价大幅拉升5.18%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为2.33%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227001624a4cc36e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227001624a4cc36e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614913620","title":"Cardiff Oncology, Inc.盘中异动 早盘大幅上涨6.47%报1.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614913620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614913620?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:34","pubTimestamp":1772030062,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日22时34分，Cardiff Oncology, Inc.股票出现波动，股价快速上涨6.47%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225223422a4c7a954&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225223422a4c7a954&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607038422","title":"Cardiff Oncology, Inc.盘中异动 早盘快速跳水5.00%报1.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607038422","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607038422?lang=zh_cn&edition=full","pubTime":"2026-01-28 23:05","pubTimestamp":1769612716,"startTime":"0","endTime":"0","summary":"北京时间2026年01月28日23时05分，Cardiff Oncology, Inc.股票出现波动，股价急速下跌5.00%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.76%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128230517a460e861&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128230517a460e861&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177984979","title":"Cardiff Oncology公司：数据支持一线RAS突变MCR注册项目中选定30毫克Onvansertib剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1177984979","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177984979?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:07","pubTimestamp":1769515640,"startTime":"0","endTime":"0","summary":"Cardiff Oncology公司近日公布的研究数据，为在一线治疗RAS突变转移性结直肠癌（MCR）的注册项目中选用30毫克Onvansertib剂量提供了有力支持。这一剂量选择基于临床研究中的有效性和安全性数据，有望推动该药物后续的注册审批进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157697690","title":"Cardiff Oncology, Inc.：Onvansertib联合FOLFIRI/Bev一线标准疗法显示总体缓解率呈剂量依赖性改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1157697690","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157697690?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:06","pubTimestamp":1769515570,"startTime":"0","endTime":"0","summary":"Cardiff Oncology, Inc.最新研究数据显示，将Onvansertib添加到FOLFIRI联合贝伐珠单抗（Bevacizumab）的一线标准治疗方案中，可观察到患者总体缓解率（Overall Response Rate, ORR）呈现出明显的剂量依赖性提升。这一发现进一步支持了Onvansertib在该治疗组合中的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161858053","title":"Cardiff Oncology宣布管理层变动 公司迈入晚期临床开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1161858053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161858053?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:04","pubTimestamp":1769515495,"startTime":"0","endTime":"0","summary":"随着公司战略重心向晚期临床开发阶段转移，Cardiff Oncology, Inc.今日宣布对其高管团队进行重要调整。此次人事变动旨在优化组织架构，为后续关键性临床试验的推进提供更强有力的领导支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","CTMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159387466","title":"Cardiff Oncology公布在ASH 2025中与Onvansertib联合进行的慢性骨髓单核细胞白血病的临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1159387466","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159387466?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:06","pubTimestamp":1765227976,"startTime":"0","endTime":"0","summary":"Cardiff Oncology公布在ASH 2025中与Onvansertib联合进行的慢性骨髓单核细胞白血病的临床试验数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588701535","title":"Cardiff Oncology, Inc.盘中异动 早盘大幅跳水5.04%报2.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701535?lang=zh_cn&edition=full","pubTime":"2025-12-01 23:24","pubTimestamp":1764602671,"startTime":"0","endTime":"0","summary":"北京时间2025年12月01日23时24分，Cardiff Oncology, Inc.股票出现波动，股价大幅下挫5.04%。截至发稿，该股报2.17美元/股，成交量7.0432万股，换手率0.10%，振幅3.95%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为1.32%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201232432a71d34ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201232432a71d34ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518847203","title":"Cardiff Oncology, Inc.盘中异动 下午盘快速下挫5.19%报3.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518847203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518847203?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:11","pubTimestamp":1741626690,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时11分，Cardiff Oncology, Inc.股票出现波动，股价快速跳水5.19%。截至发稿，该股报3.66美元/股，成交量38.3547万股，换手率0.58%，振幅5.19%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311011130a26a766f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311011130a26a766f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517452649","title":"Cardiff Oncology, Inc.2024财年实现净利润-45.43百万美元，同比减少9.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517452649","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517452649?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363258,"startTime":"0","endTime":"0","summary":"3月8日，Cardiff Oncology, Inc.公布财报，公告显示公司2024财年净利润为-45.43百万美元，同比减少9.63%；其中营业收入为683000.00美元，同比增加39.96%，每股基本收益为-0.95美元。从资产负债表来看，Cardiff Oncology, Inc.总负债14.24百万美元，其中短期债务710000.00美元，资产负债比为6.83，流动比率为7.08。机构评级：截至2025年3月8日，当前有4家机构对Cardiff Oncology, Inc.目标价做出预测，其中目标均价为14.25美元，其中最低目标价为10.00美元，最高目标价为20.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000249a2647fc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000249a2647fc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517161846","title":"Cardiff Oncology, Inc.盘中异动 早盘大幅下挫5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517161846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517161846?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:35","pubTimestamp":1741271739,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时35分，Cardiff Oncology, Inc.股票出现异动，股价急速下挫5.15%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223539963c4db0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223539963c4db0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517946697","title":"Cardiff Oncology, Inc.盘中异动 急速上涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517946697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517946697?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:32","pubTimestamp":1741188766,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时32分，Cardiff Oncology, Inc.股票出现异动，股价急速拉升5.09%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.20%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233246abe9c451&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233246abe9c451&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516559796","title":"Cardiff Oncology, Inc.盘中异动 快速下挫5.07%报4.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516559796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516559796?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:12","pubTimestamp":1741018338,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时12分，Cardiff Oncology, Inc.股票出现波动，股价大幅跳水5.07%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为3454.38%、151.02%、139.72%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Radiopharm Theranostics Limited，振幅分别为206.20%、70.53%、53.50%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304001219abe65461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304001219abe65461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320288","title":"Cardiff Oncology, Inc.盘中异动 大幅上涨5.30%报4.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514320288?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:35","pubTimestamp":1740753340,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时35分，Cardiff Oncology, Inc.股票出现异动，股价急速上涨5.30%。截至发稿，该股报4.28美元/股，成交量15.4379万股，换手率0.23%，振幅3.75%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223540abe0ebfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223540abe0ebfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118930078","title":"Cardiff Oncology第四季度GAAP每股收益$(0.21)优于预期$(0.24)，销售额$151.00K优于预期$94.17K","url":"https://stock-news.laohu8.com/highlight/detail?id=1118930078","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118930078?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:38","pubTimestamp":1740692305,"startTime":"0","endTime":"0","summary":"Cardiff Oncology报告季度每股亏损$，优于分析师一致预期的$，增长了12.5%。与去年同期的销售额$156.00千相比下降了3.21%。以上内容来自Benzinga Earnings专栏，原文如下：Cardiff Oncology  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 12.5 percent. This is unchanged from the same period last year.  The company reported quarterly sales of $151.00 thousand which beat the analyst consensus estimate of $94.17 thousand by 60.35 percent.  This is a 3.21 percent decrease over sales of $156.00 thousand the same period last","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cardiff Oncology第四季度GAAP每股收益$(0.21)优于预期$(0.24)，销售额$151.00K优于预期$94.17K","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514163386","title":"Cardiff Oncology, Inc.盘中异动 早盘股价大跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514163386","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514163386?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:57","pubTimestamp":1740668275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时57分，Cardiff Oncology, Inc.股票出现波动，股价快速下跌5.16%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227225755989515c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227225755989515c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514517328","title":"Cardiff Oncology, Inc.盘中异动 快速上涨5.20%报4.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514517328","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514517328?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:12","pubTimestamp":1740582765,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时12分，Cardiff Oncology, Inc.股票出现异动，股价快速上涨5.20%。截至发稿，该股报4.45美元/股，成交量10.325万股，换手率0.16%，振幅4.96%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226231245963157ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226231245963157ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiffoncology.com","stockEarnings":[{"period":"1week","weight":0.0659},{"period":"1month","weight":0.0289},{"period":"3month","weight":0.1056},{"period":"6month","weight":-0.1232},{"period":"1year","weight":-0.3819},{"period":"ytd","weight":-0.3665}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cardiff Oncology, Inc.于2002年4月26日在佛罗里达州注册成立。该公司是一家临床阶段的生物技术公司，利用PLK1抑制（一种经过充分验证的肿瘤药物靶点）开发跨越一系列未满足医疗需求的癌症的新疗法。该公司的目标是通过onvansertib、公司口服和高选择性PLK1抑制剂以及标准护理疗法的治疗组合来针对肿瘤脆弱性。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.023989},{"month":2,"riseRate":0.5,"avgChangeRate":0.28397},{"month":3,"riseRate":0.357143,"avgChangeRate":0.075052},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.062128},{"month":5,"riseRate":0.5,"avgChangeRate":0.050575},{"month":6,"riseRate":0.384615,"avgChangeRate":0.287657},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.07931},{"month":8,"riseRate":0.571429,"avgChangeRate":0.100833},{"month":9,"riseRate":0.285714,"avgChangeRate":0.016213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014863},{"month":11,"riseRate":0.357143,"avgChangeRate":0.032453},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.01141}],"exchange":"NASDAQ","name":"Cardiff Oncology, Inc.","nameEN":"Cardiff Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiff Oncology, Inc.(CRDF)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cardiff Oncology, Inc.(CRDF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cardiff Oncology, Inc.,CRDF,Cardiff Oncology, Inc.股票,Cardiff Oncology, Inc.股票老虎,Cardiff Oncology, Inc.股票老虎国际,Cardiff Oncology, Inc.行情,Cardiff Oncology, Inc.股票行情,Cardiff Oncology, Inc.股价,Cardiff Oncology, Inc.股市,Cardiff Oncology, Inc.股票价格,Cardiff Oncology, Inc.股票交易,Cardiff Oncology, Inc.股票购买,Cardiff Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiff Oncology, Inc.(CRDF)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cardiff Oncology, Inc.(CRDF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}